WASHINGTON, DC, April 16, 2010 - Life Technologies' genomic sequencing and analysis products and a number of presentations specific to oncology research, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR).  The meeting is taking place Saturday, April 17 through Wednesday, April 21 at the Walter E. Washington Convention Center in Washington, DC.

During the AACR conference, Life Technologies will emphasize its commitment to cancer research with multiple presentations, including the commercial release of the research-use-only (RUO) KRAS and BRAF Mutation Analysis Reagents under the Life Technologies brand, Applied Biosystems®. The reagent sets can be analyzed using the 3500 Series Genetic Analyzer.

Work conducted by a team led by Howard Doong, Ph.D, of TrimGen Corporation will present results of Life Technologies’ new KRAF and BRAF mutation analysis reagent sets at a late-breaker poster session on Tuesday, April 20 from 9 a.m. to noon. Using these reagent sets for KRAS analysis, Dr. Doong will report on his study comparing KRAS mutations observed in 118 formalin-fixed paraffin-embedded tumor samples. Mutations in KRAS and BRAF oncogenes have been implicated to have an association with certain cancer treatments.

In addition, several abstracts and papers using the SOLiD 4 System will be presented at the meeting, including a presentation by Dr. Victor E. Velculescu of The Johns Hopkins Oncology Center. Dr. Velculescu is using the system to identify personalized biomarkers for solid tumors.

This approach may one day provide broadly applicable improvements to the clinical management of cancer patients. The high accuracy of the SOLiD 4 System is critical in discovery of rare variants in heterogeneous tumor samples.

Life Technologies’ at AACR Breakout Sessions

AACR presentations demonstrate the broad utility, superior accuracy and reliability of Life Technologies’ tools across multiple generations of genetic sequencing and analysis technology – qualities that are important to oncology research from discovery to the clinic. These presentations include:

Saturday, April 17

  • Conference Session “Next-Generation Sequencing: Data Analysis and Applications"

          3:15 p.m. – 5:15 p.m., Room 145

          Chairperson: Dr. Victor Velculescu, John Hopkins Oncology Center

  • Conference Session #MW12: “SOLiD Sequencing With Error Correction Codes: In Pursuit of Somatic Mutation Detection”

          3:45 p.m. – 4:05 p.m., Room 145

          Presenter: Kevin McKernan, Life Technologies

Monday, April 19

  • Poster # 2212/1: “A Genomic Portrait of Tumor Progression Using Next Generation Sequencing”

          2:00 p.m. – 5:00 p.m., Exhibit Hall A-C, Poster Section 10

          Presenter: Dr. Jun S. Wei, National Cancer Institute

  • Presentation #2196: “Genome-Wide Analysis of DNA Methylation Patterns in Formaldehyde-Fixed Paraffin-Embedded (FFPE) Human Tumor Specimens”

          2:00 p.m. – 5:00 p.m., Exhibit Hall A-C, Poster Section 9, Board #15

          Presenter: Dr. Fabienne Brenet, Weill-Cornell College

Tuesday, April 20

  • Presentation #2957: “Characterization of Oral Tumors by Massively Parallel Litgation Sequencing”

          9:00 a.m. – Noon, Exhibit Hall A-C, Poster Section 1, Board #18

          Presenter: Dr. Rebecca R. Laborde, Mayo Clinic

  • Poster # 2117/8: “Identification of Rare KRAS Mutations in Codons 12 and 13 by Shifted Termination Assay,” Late-Breaking Research: Clinical Research 2.

          9.00 am – Noon, Exhibit Hall A-C, Poster Section 40. Abstract number: LB-222.

          Presenter: Julian Walker, Life Technologies

For more information on our technologies, please stop by our booth #534.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Life Technologies Contacts

Patty Zamora
Heather Platisha